{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:37:13Z","timestamp":1791067033000,"version":"4.1.0"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,2,1]]},"abstract":"<jats:p> Purpose: Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFN\u03b12b) in HCC was launched with the assumption that it could be tolerated by cirrhotics. <\/jats:p><jats:p> Patients and Methods: Forty-three patients with HCC (34), and fibrolamellar HCC (FLHCC; nine) were treated with continuous intravenous (IV) FU (200 mg\/m<jats:sup>2<\/jats:sup>\/d \u00d7 21 every 28 days) and subcutaneous (SC) rIFN\u03b12b (4 million U\/m<jats:sup>2<\/jats:sup>) three times weekly. Survival was determined in all 43 patients, and response could be assessed in 28 HCC and 8 FLHCC patients. <\/jats:p><jats:p> Results: The median ages of the patients were 63.5 and 19 years among HCC and FLHCC patients, respectively. Liver cirrhosis was present among 71% of HCC patients but among none of the FLHCC patients. Nine of 36 (25%; four of 28 [14%] HCC patients; five of eight [62.5%] FLHCC patients) patients in which a response could be assessed had a complete response (CR; one patient with FLHCC and no patients with HCC) or partial response (PR; eight patients [four HCC and four FLHCC patients]). Four HCC patients underwent resection, and two had a histologic CR; one HCC patient with a PR underwent orthotopic liver transplantation. One FLHCC patient also underwent resection without clear margins. Overall median survival was 19.5 months (95% confidence interval [CI], 11.2 to 27.8 months); median survival was 15.5 months (95% CI, 8.5 to 22.5 months) among HCC patients, and that of FLHCC patients was 23.1 months (95% CI, 10.3 to 35.9 months). Overall grade 3 or 4 toxicity included stomatitis (32.6%), fatigue (4.7%), and hematologic toxicity (9.3%). <\/jats:p><jats:p> Conclusion: Continuous IV FU and thrice-weekly SC rIFN\u03b12b are an effective treatment, especially for FLHCC, and may have a neoadjuvant role in this disease. This regimen has activity in HCC and can be tolerated even by cirrhotic patients. <\/jats:p>","DOI":"10.1200\/jco.2003.10.103","type":"journal-article","created":{"date-parts":[[2003,1,30]],"date-time":"2003-01-30T21:34:31Z","timestamp":1043962471000},"page":"421-427","source":"Crossref","is-referenced-by-count":157,"title":["Phase II Trial of Systemic Continuous Fluorouracil and Subcutaneous Recombinant Interferon Alfa-2b for Treatment of Hepatocellular Carcinoma"],"prefix":"10.1200","volume":"21","author":[{"given":"Yehuda Z.","family":"Patt","sequence":"first","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal M.","family":"Hassan","sequence":"additional","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Lozano","sequence":"additional","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Nicolas","family":"Vauthey","sequence":"additional","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Curley","sequence":"additional","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Ellis","sequence":"additional","affiliation":[{"name":"From the Department of Gastrointestinal Medical Oncology and Digestive Diseases, the Department of Surgical Oncology, and the Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401001"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.21.3227"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.50.1.7"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908193410802"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36780"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(83)90352-8"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00428.x"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Melia WM, Johnson PJ, Williams R: Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin. Cancer 5:206,1983\u2013210,","DOI":"10.1002\/1097-0142(19830115)51:2<206::AID-CNCR2820510206>3.0.CO;2-P"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.392"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199904000-00024"},{"key":"R12","unstructured":"Leung TW, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676,1999\u20131681,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-9-199911020-00011"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91739-X"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02463.x"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02634.x"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1908"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1230"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050951"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050522"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1769"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.4.921"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.10.2674"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010551"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940801)74:3<958::AID-CNCR2820740326>3.0.CO;2-X"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)81011-3"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.164.5.7717223"},{"key":"R29","unstructured":"Hassan M, Patt YZ, Lozano R, et al: Continuous I. V. infusion of 5-fluorouracil (5-FU) and subcutaneous (S. C.) recombinant interferon alpha 2b (rIFN\u03b1 2b) is an active regimen in fibrolamellar hepatocellular carcinoma (FLHCC). Proc Am Soc of Clin Oncol , 19: 2000 (abstr 122)"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.1-2.203"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.202.1.8988182"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1042\/bj3340001"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1038\/338557a0"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1021\/bi00163a024"},{"key":"R38","unstructured":"Miyadera K, Sumizawa T, Haraguchi M, et al: Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor\/thymidine phosphorylase. Cancer Res 55:1687,1995\u20131690,"},{"key":"R39","unstructured":"Folkman J, Ingber D: Inhibition of angiogenesis. Semin Cancer Biol 3:89,1992\u201396,"},{"key":"R40","unstructured":"Sgonc R, Fuerhapter C, Boeck G, et al: Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Allergy Immunol 117:209,1998\u2013214,"},{"key":"R41","unstructured":"Dinney CP, Bielenberg DR, Perrotte P, et al: Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58:808,1998\u2013814,"},{"key":"R42","unstructured":"Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685,1998\u2013690,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.10.103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:32:00Z","timestamp":1653510720000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.10.103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2,1]]}},"alternative-id":["10.1200\/JCO.2003.10.103"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.10.103","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,1]]}}}